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Prediction in idiopathic membranous nephropathy. syndrome in Caucasian adults [1]. Approximately 25%
Background. Results of the prognosis of idiopathic membra- of the patients will enter into spontaneous remission,
nous nephropathy are conflictive and prevent an effective risk whereas approximately one third to one half will develop
stratification. These conflicts are explained in part by insuffi-
end-stage renal failure (ESRF) or die from complicationscient consideration of methodological principles for prognostic
of the nephrotic syndrome. A demarcation of the differ-research. This cohort study is aimed at identifying clinical pre-
dictors for risk stratification while paying particular attention ent risk strata is needed in order to apply new treatments
to methodology. to targeted high-risk patients who will be involved in
Methods. We studied 120 patients with idiopathic membra- future clinical trials, for whom the expected benefit might
nous nephropathy. Baseline data were extracted at the time
outweigh the risk of a potentially harmful therapy [2, 3].of diagnostic renal biopsy, and patients were followed prospec-
Discrepancies in the hitherto identified predictors, how-tively. Predictors were identified for the end points end-stage
ever, impede a uniform and effective risk stratification.renal failure (ESRF) and ESRF or death.
Results. From the 120 patients followed for a median of five Previous data have shown that the conflicting results on
years (1 to 24 years), 19% developed end-stage renal failure the prognosis of idiopathic membranous nephropathy
or deterioration of renal function. Proteinuria of more than are explained in part by insufficient consideration of3.5 g/day persisted in 34%, and 47% were in complete or partial
established methodological principles for prognostic re-remission. The Kaplan–Meier estimated probability of renal
search. [4]. The principles most often not consideredsurvival was 91 6 3% at five years and 75 6 6% at ten years.
The predictors for the primary outcome, ESRF, identified in and yet essential for interpretability and applicability of
a Cox proportional hazards model, were histological stage results are: (a) analysis for the definite end point end-
(Ehrenreich–Churg) III-IV (hazard ratio 5.3, CI 1.9 to 15.0, P 5 stage renal failure (ESRF); (b) adequate analysis of base-0.002) and nephrotic syndrome (hazard ratio 7.9, CI 1.1 to 61.5,
line severity, including severity of renal disease and se-P 5 0.04); the predictors for the secondary outcome, ESRF
verity of comorbidity; (c) a multivariable analysis for theor patient death, were histological stage III-IV (hazard ratio 2.8,
CI 1.3 to 6.0, P 5 0.008), nephrotic syndrome (hazard ratio identification of predictors; and (d) an analysis for the
3.0, CI 1.1 to 8.0, P 5 0.003) and comorbidity (hazard ratio impact of treatment.
2.8, CI 1.3 to 5.9, P 5 0.007). Nephrotic syndrome and histologi- The aim of this study was to evaluate the long-termcal stage III-IV allowed the demarcation of the high-risk group
prognosis of idiopathic membranous nephropathy, andfrom the remaining patients (P , 0.0001).
to identify predictors in a large and unselected cohortConclusion. Histological stage, nephrotic syndrome, and
comorbidity predict end-stage renal failure or death in idio- while paying particular attention to the consideration
pathic membranous nephropathy. Identification of the high- of established methodological principles for prognostic
risk group at the time of diagnostic renal biopsy will permit research [4–7].
appropriate treatment to be targeted to the patients who might
benefit the most from the therapy in future clinical trials.
METHODS
Study population
Results are conflicting for the prognosis of membranous
We identified 175 adult patients who had histologicallynephropathy, the most common cause of the nephrotic
proven membranous nephropathy by renal biopsy be-
tween 1971 and 1994 in four participating nephrology
centers (University Erlangen-Nu¨rnberg and the nephrol-Key words: risk stratification, membranous nephropathy, multivariable
analysis, prognostic research, cohort studies. ogy units in Bamberg, Bayreuth, and Neumarkt). The
histological diagnosis was based on light microscopy andReceived for publication July 16, 1998
either immunohistochemistry or electron microscopy.and in revised form February 25, 1999
Accepted for publication March 1, 1999 The histological staging was made according to the crite-
ria by Ehrenreich et al [8]. In addition, the severity of 1999 by the International Society of Nephrology
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tubulointerstitial lesions and focal glomerulosclerosis g/day, with a decrease in serum albumin to less than 30
g/liter and edema. Hypertension was defined as diastolicwas assessed [9]. Twelve patients had to be excluded
because their medical records could not be retrieved. blood pressure $ 90 mm Hg and/or systolic blood pres-
sure $ 160 mm Hg. Follow-up data were assessed in theThe identification of secondary forms of membranous
nephropathy led to the exclusion of 31 patients after outpatient department or by the patient’s own physician
according to a uniform protocol. The information on theapplying a structured checklist for clinical, laboratory,
and histological evidence of underlying systemic disease end points was verified by consulting additional sources,
such as medical records from other hospitals or privateor associated drugs to each patient. Because data were
incomplete for 12 patients, the final prognostic analysis physicians, and the death registry.
included 120 of the 132 patients with idiopathic membra-
Statistical analysisnous nephropathy. The minimal follow-up was 12 months.
Supportive therapy or immunosuppressive treatment To test our hypothesis about the association of severity
of disease and other covariates with the end point ESRF,was administered at the treating physician’s discretion.
The following immunosuppressive therapies were used: we conducted a bivariate analysis. We used the Student’s
t-test for comparison of means and the chi-square test100 to 150 mg prednisone on alternate days for a three-
month course [10], a six-month course of corticosteroids (or Fisher’s exact test) for data expressed as proportions.
The maintenance of renal function without ESRF wasalternated with chlorambucil at a dose of 0.2 mg/kg/day
every other month [11], cyclophosphamide at a maxi- estimated by survival analysis according to the Kaplan–
Meier method [19]. The log-rank test was used for com-mum dose of 2 mg/kg/day [12, 13], cyclosporine A at an
initial dose of 4 mg/kg, with an adjustment of the dose parison of survival curves. For all analyses, a two-tailed
P value of less than 0.05 was considered to indicateaccording to serum levels [14, 15], and azathioprine at
a dose of 2 mg/kg/day for a sixth-month course. statistical significance.
Variables for which statistically significant differences
Outcomes in renal survival were found and those of special clinical
importance were identified for inclusion in multivariableThe primary outcome of this study was the definite
end-point “ESRF,” which required renal replacement analysis. The variables used in multivariable analysis
were expressed using a binary scale, such as absent/pres-therapy. Because of the potential bias in assigning, and
the difficulties in verifying, cause-specific deaths [5, 16], ent, and coded as 0/1. The semiquantitative estimates of
the degree of focal glomerulosclerosis and tubulointersti-the analysis for the secondary end point, “ESRF and total
death,” was repeated to see if the predictors changed. tial lesions [9] were coded for analysis as 0/1 for the catego-
ries absent (none or mild) and present (moderate orIn addition, we analyzed for the surrogate end-point
“deterioration of renal function,” which was defined as marked). Comorbidity was coded as 0/1/2 for the catego-
ries none, intermediate, and severe. We used the Coxa doubling of baseline serum creatinine values. The out-
come “partial remission” was defined as proteinuria of proportional hazards model choosing a forward stepwise
procedure [20]. The results from multivariable analysis0.2 to 2.0 g/day. “Complete remission” was defined as
proteinuria of less than 0.2 g/day. were expressed by the hazard ratio as an index for quanti-
tative significance and the 95% confidence intervals (CI)
Data collection and definitions and P values as an index for statistical significance. The
identified predictors were evaluated on their consistencyThe baseline data at the time of first diagnostic renal
biopsy were compiled from the medical records by two in additional multivariable analyses performed (a) in the
entire cohort and (b) in the restricted cohort of patientstrained extractors who were blinded to the outcome.
Patient characteristics included: (a) demographic vari- with proteinuria of more than 3.5 g/day, for the end
points “deterioration of renal function” and “ESRF orables; (b) clinical and laboratory data reflecting the se-
verity of renal functional impairment; (c) severity of death.” The identified predictors were then used to re-
classify the patients for risk stratification.histological lesion, including glomerular lesion [8], tubu-
lointerstitial lesion, and focal glomerulosclerosis [9]; (d) All statistical analyses, including the Cox proportional
hazards model, were performed with the SPSS (Statisti-comorbid diseases; and (e) treatment. The severity of co-
morbidity was classified according to the validated index cal Package for the Social Sciences) program (version 6.1).
by Kaplan and Feinstein [17]. Grades of 0, 1, 2, or 3 were
assigned for the severity of the highest-ranked disease or
RESULTS
condition. Because patients with grade 1 or 2 ratings had
Baseline characteristicssimilar mortality rates at five years in the test population
as in the current study, these two grades were combined The median duration of follow-up of the 120 Cauca-
sian patients with idiopathic membranous nephropathyfor all analyses [17, 18]. The “nephrotic syndrome” was
defined as urinary protein excretion of more than 3.5 was 5 years, ranging from 1 to 24 years. The proportion
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Table 1. Baseline characteristics of 120 patients with
idiopathic membranous nephropathy
Age years 46615
Age distribution (years) % of patients
,30 18
30–39 18
40–49 20
50–59 21
60–69 20
$70 3
Sex male /female 89/31
Hypertension % of patients 49
Edema % of patients 69
Serum creatininea mg/dl 1.260.6
Urinary protein excretion g /24 hr 8.266.2
Degree of proteinuria (g /24 hr) % of patients
0.21 to ,3.5 16
3.5 to ,10.0 55
$10.0 29
Serum albumin g /liter 2.660.7
Serum cholesterolb mg/dl 4076129
Nephrotic syndrome % of patients 63
Histologic stagec % of patients Fig. 1. Kaplan–Meier estimated probability of survival without end-
I 33 stage renal failure.
II 48
III 18
IV 1
Tubulointerstitial lesions % of patients 31
Focal glomerulosclerosis % of patients 54 of deterioration of renal function was 19% (23 patients)
Comorbidity graded % of patients among the 120 patients. Proteinuria of more than 2 g/day
None 36
persisted in 34% (41 patients) without a deterioration ofIntermediate 59
Severe 5 renal function. Complete or partial remission was pres-
Plus-minus values are means 6 sd. ent in 47% of the patients. Twenty patients were in
a To convert values for creatinine to micromoles per liter, multiply by 88.4 complete remission (proteinuria less than 0.2 g/day) andb To convert values for cholesterol to millimoles per liter, multiply by 0.0259
c Staging system according to Ehrenreich and Churg [8] 36 patients were in partial remission (proteinuria 0.2 to
d Comorbidity according to the classification by Kaplan and Feinstein [17, 18] 2 g/day). At the end of the follow-up period, 17 patients
(14%) had died, 3 after starting hemodialysis and 2 after
renal function had deteriorated; 11 patients had persis-
tent proteinuria without deterioration of renal function,of men to women was 3:1 (Table 1). The majority of
and 1 patient had been in partial remission. The causespatients (63%) had a nephrotic syndrome at presenta-
of death were pulmonary embolism in three patients,tion. The median value for proteinuria was 6.6 g/day. A
mesenterial infarction in one, stroke in one, acute coro-severe histological lesion (glomerular stage III-IV) was
nary event in one, and cancer in one. For the remainingobserved in 19% of patients at the time of renal biopsy.
10 patients, the cause of death was unknown.Hypertension was present in 49%. The serum cholesterol
The estimated probability of renal survival, that is,averaged 407 6 129 mg/dl. Various immunosuppressive
survival without ESRF, based on the Kaplan–Meier anal-regimens were prescribed to 71% of patients after histo-
ysis, was 91 6 3% at 5 years and 75 6 6% at 10 yearslogical diagnosis. The analysis for homogeneity of the
(Fig. 1). The estimated probability of retaining adequatepopulations included at the four nephrology units showed
renal function without deterioration (neither ESRF northat there was no significant difference with regards to
doubling of baseline serum creatinine) was 89 6 3% atthe mean age, sex, and baseline severity of disease. In
5 years and 66 6 7% at 10 years. For the secondary end-addition, when taking into account the baseline severity
point renal and patient survival, the probabilities wereof disease, the proportions of patients treated were not
84 6 4% at 5 years and 62 6 7% at 10 years, respectively.significantly different between the nephrology units (data
not shown).
Effect of baseline characteristics on outcome
Long-term outcome events The results from bivariate analysis showed a significant
association of baseline serum creatinine, serum albumin,During the follow-up period, ESRF requiring renal
proteinuria, nephrotic syndrome, and histological stagereplacement therapy developed in 15 patients after a
to the primary outcome ESRF (Table 2). Identical resultsmean duration of 5.5 6 3.2 years (range, 1 to 12.8 years).
were obtained for the end point deterioration of renalBaseline serum creatinine doubled in eight patients by
the final follow-up measurement. Thus, the overall rate function. The clinically relevant composite variable
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Table 4. Predictors for end-stage renal failure andTable 2. Association between baseline characteristics and the
outcome end-stage renal failure (ESRF) end-stage renal failure or death in 120 patients with
idiopathic membranous nephropathy
No ESRF ESRF
Variables N 5 105 N 5 15 P value Hazard ratio
End points and variables (95% CI) P value
Age years 43615 46 615 NS
Male/female 79/26 10/5 NS End-stage renal failure
Histologic stageSerum creatinine .1.5 mg/dl 11% 33% 0.04
Serum albumin ,3 g /dl 72% 100% 0.02 Stage I or II vs. III or IV (0/1)a 5.3 (1.9–15.0) 0.002
Nephrotic syndromeProteinuria .3.5 g /day 75% 100% 0.04
Nephrotic syndrome 58% 93% 0.01 Absent vs. present (0/1)a 7.9 (1.1–61.5) 0.04
End-stage renal failure or deathSerum cholesterol $ 300 mg/dl 80% 100% NS
Hypertension 48% 60% NS Histologic stage
Stage I or II vs. III or IV (0/1)a 2.8 (1.3–6.0) 0.008Histologic stage III-IVa 12% 60% 0.0001
Tubulointerstitial lesions 25% 64% 0.03 Nephrotic syndrome
Absent vs. present (0/1)a 3.0 (1.1–8.0) 0.003Focal glomerulosclerosis 49% 82% 0.05
Vascular burdenb 18% 40% NS Comorbidity
None vs. intermediate vs. severe (0/1/2)a 2.8 (1.3–5.9) 0.007Comorbidityc
None 37% 27% CI denotes confidence interval. aClassification of the variables used in the Cox
Intermediate 58% 67% NS proportional hazards model; the coding is indicated in parentheses.
Severe 5% 7%
The abbreviation NS is not significant.
a Staging system according to Ehrenreich and Churg [8]
b Vascular burden 5 presence of moderate hypertension and cholesterolemia $
(Table 4): histologic stage III-IV (hazard ratio 5.3, CI300 mg/dl
c Comorbidity classified according to the system by Kaplan and Feinstein [17, 18] 1.9 to 15.0, P 5 0.002) and nephrotic syndrome (hazard
ratio 7.9, CI 1.1 to 61.5, P 5 0.04). The variables age,
sex, vascular burden, serum creatinine, comorbidity, and
immunosuppressive treatment were not predictive. TheTable 3. Association between various therapeutic strategies and the
outcome end-stage renal failure (ESRF) results were consistent for the end point deterioration
of renal function. Figure 2 demonstrates the differentNo ESRF ESRF
Kaplan–Meier curves for renal survival according to his-Therapeutic strategy N 5 105 N 5 15 P value
tological stage and presence or absence of the nephroticNo therapy or supportive therapy
(diet, ACE inhibitors, NSAID) 33 (31%) 2 (13%) NS syndrome.
Immunosuppressive therapy 72 (69%) 13 (87%) NS To reveal bias that may have occurred from censoring
Steroids 23 (22%) 5 (33%) NS
patients who have died but might have been at risk forCyclophosphamide 6 steroids 18 (17%) 3 (20%) NS
Chlorambucil 6 steroids 25 (24%) 2 (13%) NS developing the end point ESRF, we repeated the analysis
Cyclosporine A 4 (4%) 2 (13%) NS for the secondary end point, that is, ESRF or death. In
Azathioprine 2 (2%) 1 (7%) NS
addition to the variables that reflect renal functional
Abbreviations are: ACE, angiotensin converting enzyme; NSAID, nonsteroi- impairment, we found that hypertension, vascular bur-dal anti-inflammatory drugs; NS, not significant.
den, and comorbidity were significantly associated to
renal and patient death. Multivariable analysis identified
histological stage III-IV (hazard ratio 2.8, CI 1.3 to 6.0,
P 5 0.008), nephrotic syndrome (hazard ratio 3.0, CI 1.1“vascular burden,” defined as the presence or absence
of moderate or severe hypertension together with hyper- to 8.0, P 5 0.003), and comorbidity (hazard ratio 2.8, CI
1.3 to 5.9, P 5 0.007) as the only predictors for renalcholesterolemia $ 300 mg/dl, was associated with ESRF,
but did not achieve statistical significance (P 5 0.06). or patient death (Table 4). Figure 3 demonstrates the
different Kaplan–Meier curves for renal and patient sur-There was no significant association between immuno-
suppressive therapy and the outcome ESRF, as shown vival according to severity of comorbidity. No additional
predictors were identified for the subgroup of patientsin Table 3. The proportion of patients on steroids and
cytotoxic drug therapy was not significantly different be- with higher grade proteinuria (more than 3.5 g/day). All
of the multivariable analyses were performed with andtween the group that developed ESRF and the group
that did not develop ESRF. without the treatment variable included to check if the
identified predictors change [4, 5]. ImmunosuppressiveBefore evaluating the candidate predictors in the multi-
variable analysis, the variables were categorized, and cut therapy did not show an impact on the predictors in any
of the analyses performed.points were chosen that were clinically meaningful and
statistically relevant. When the bivariately significant
Demarcation of risk stratavariables entered the Cox proportional hazards model
together with the clinically important variables (vascular Using the predictors identified in multivariable analy-
sis, we performed a targeted cross-stratification of theburden, comorbidity, immunosuppressive treatment,
age, and sex), only two predictors for ESRF emerged entire cohort. We assigned patients with the two renal
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Fig. 2. (A) Kaplan–Meier estimated probability of renal survival (survival without end-stage renal failure) according to presence (solid line; N 5 75)
or absence (dashed line; N 5 45) of the nephrotic syndrome (P 5 0.005). (B) Kaplan–Meier estimated probability of renal survival according to
stage of histological lesion, stage I-II (dashed line; N 5 98) versus stage III-IV (solid line; N 5 22; P , 0.001) [8]. Probabilities were analyzed
according to the log-rank test.
Table 5. Rate of outcome events according to three risk groups
Deterioration End-stage
End-stage of renal renal failure
Risk groupa N renal failure functionb or death
High risk 15 8 (53%)c 9 (60%)c 10 (67%)c
Intermediate risk 67 7 (10%)d 13 (19%)d 15 (22%)d
Low risk 38 0 (0%) 1 (3%) 3 (8%)
a High risk denotes patients with two renal risk factors: nephrotic syndrome and
histologic stage III-IV. Intermediate risk denotes patients with either nephrotic
syndrome or histologic stage III-IV. Low risk denotes patients without nephrotic
syndrome and histologic stage I-II. For detailed description see text.
b Deterioration of renal function is defined as a doubling of baseline serum
creatinine. The end point includes patients with a doubled baseline serum creati-
nine and patients with end-stage renal failure.
c P , 0.005 high risk vs. intermediate risk group for all three end points
d P , 0.05 intermediate risk vs. low risk group for the end points end-stage
renal failure and deterioration, P 5 0.07 for the end point end-stage renal failure
or death
predictors, nephrotic syndrome and histological stage
III-IV, to the high risk group. Patients with one renal
predictor were assigned to the intermediate risk group,
and patients without predictors comprised the low-risk
group. The results showed a distinct demarcation of the
three risk groups with quantitatively impressive gradi-
Fig. 3. Kaplan–Meier estimated probability of renal survival according ents (Table 5). The rate of patients with ESRF at the
to severity of comorbidity [17]. Symbols are: (short dashed line) no end of follow-up was 53% in the high-risk group, 10%
comorbidity, N 5 43; (long dashed line) intermediate comorbidity, N 5
in the intermediate-risk group, and 0% in the low-risk71; (solid line) severe comorbidity; N 5 6. Probability was analyzed
according to the log-rank test (P 5 0.02). group. The overall predictive accuracy of using these
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cally pertinent predictors. First, a large and unselected
patient cohort with idiopathic membranous nephropa-
thy, diagnosed in four nephrology centers that provide
health service for an entire region of about four million
inhabitants, was available for study. Second, the patients
included in this study reflected the entire spectrum of
disease severity, as shown by the distribution of baseline
characteristics. Third, special emphasis was given to ap-
plying the established principles for prognostic research
that have often been insufficiently considered in previous
studies [4]. Strict diagnostic criteria were applied; the
unequivocal outcome ESRF was the primary end point
analyzed after a long follow-up time, extending up to 24
years and with a median of five years. To our knowledge,
this is the first study on prognosis of membranous ne-
phropathy that includes in its analysis all of the important
variables reflecting baseline severity of renal disease and
severity of comorbidity. Predictors were identified by
multivariable analysis while taking into account the po-
tential impact of treatment on predictor variables. Fi-
nally, the identified predictors allowed the demarcation
of the high-risk group from the remaining patients, which
might prove to be useful for future risk stratification and
design of therapeutic trials.
Fig. 4. Kaplan–Meier estimated probability of renal survival according
The results of this study show a relatively benign long-to three different risk groups. Symbols are: (solid line) high risk patients
with two renal risk factors present, that is, nephrotic syndrome and term prognosis of idiopathic membranous nephropathy.
histologic stage III-IV, N 5 15; (short dashed line) intermediate risk The probability of being alive without ESRF was 91%patients with either nephrotic syndrome or histological stage III-IV, N 5
at 5 years and 75% at 10 years; the probability of being67; (long dashed line) low risk patients without nephrotic syndrome
and histologic stage I-II, N 5 38. The probability is according to the in complete or partial remission was 25% at 5 years and
log-rank test (P , 0.0001). 56% at 10 years. Similar results have been observed by
Schieppati et al, who reported a probability of survival
without ESRF of 88% at five years and 73% at eight
years in untreated patients [21].two renal predictors for assigning patients to the high-
For the prognostic analysis we chose the primary endand low-risk groups for ESRF was 88%. The correspond-
point to be renal death and the secondary end point,ing Kaplan–Meier renal survival curves were markedly
renal death or patient death. The purpose of performingdifferent (log-rank P , 0.001), as shown in Figure 4.
the latter analysis was twofold: (a) to evaluate whetherSimilar survival curves and similar gradients could be
or not the predictors remain consistent when total deathsobserved for the secondary end point, that is, renal or
were added to the end point ESRF, and (b) to preventpatient death, as well as for deterioration of renal func-
the bias that can arise if patients are removed from thetion (log-rank, P , 0.001). When we performed the risk
cohort who might have been candidates for developingstratification with the two renal predictors and added
ESRF. The total number of deaths were included be-comorbidity, defining the high-risk stratum for the sec-
cause of the known difficulties in assigning and in veri-ondary end point ESRF or death as containing patients
fying actual causes of death.with at least two of the three multivariable predictors,
In this study, the predictors identified in multivariablethe overall predictive accuracy for renal or patient death
analyses are clinically relevant and plausible: (a) theimproved only marginally, from 81% in the model with
presence of the nephrotic syndrome and (b) histologicalthe two renal predictors compared with 82% in the
stage III-IV [8] predict the outcome ESRF; these vari-model with comorbidity added.
ables, together with (c) comorbidity, predict the outcome
ESRF or death. Regardless of the combination of these
DISCUSSION variables, they were the only ones found to be predictive
when subjected to Cox regression analysis together withThis study on prognostic factors in membranous ne-
phropathy has distinctive strengths because of the partic- the other candidates, including age, sex, hypertension,
hypercholesterolemia, tubulointerstitial lesions, focalular attention to methodology and identification of clini-
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glomerulosclerosis, serum creatinine, and immunosup- importance and is needed for a correct interpretation
pressive therapy. and application of the prognostic results. Because of the
In a recent review on prognostic factors in mem- known complexity related to the classification of severity
branous nephropathy, remarkably high odds ratios have of comorbidity [18], we applied the validated index by
been presented for factors such as glomerular stage, focal Kaplan and Feinstein [17]. When we performed the
sclerosis on biopsy, persistent proteinuria, and serum multivariable analysis for the secondary end point, that
creatinine [22]. However, these results cannot be directly is, patient or renal death, the predictive impact of comor-
compared with ours, because, as stated by the authors bidity became evident.
themselves, they combined all of the prognostic studies The identified predictors allowed the demarcation of
available that provide quantitative data in order to calcu- the high-risk group from the remaining patients in a
late odds ratios, regardless of the study quality. For most stratified analysis. The risk gradient between the high-
of these studies, established principles for prognostic risk, intermediate-risk, and low risk-groups was consis-
research have not been sufficiently considered [4]. In tent for all three end points analyzed: the primary out-
particular, only a few evaluated the impact of the pre- come, ESRF, the secondary outcome, ESRF or death,
dictors using a multivariable analysis. This heterogeneity and the surrogate end point, deterioration of renal func-
and the frequently missing information prevent an accu- tion (P , 0.001). Accordingly, the survival curves were
rate interpretation and reconciliation of the conflicting significantly different between the three risk groups (Fig.
results. When comparing our results with one of the stud- 4). The overall predictive accuracy of assigning patients
ies that showed higher compliance with the methodologi- with at least two renal risk factors (nephrotic syndrome
cal standards and identified as predictors male sex, serum and histological stage III-IV) to the high-risk group for
albumin, and prednisone [23], we might explain the dif- developing ESRF was 88%.
ferences in the identified predictors by differences ob-
In summary, we have shown that the consideration of
served in baseline severity between the two study popu-
methodological principles for prognostic research led tolations. Whereas men showed a significantly higher
the identification of clinically relevant and simple pre-baseline severity compared with women, proteinuria be-
dictors for ESRF or death in patients with idiopathicing 11.2 versus 7.1 g/day and serum creatinine being 1.8
membranous nephropathy: nephrotic syndrome, histo-versus 1.2 mg/dl [23], there was no difference in baseline
logical stage III-IV, and comorbidity. The criteria ne-severity between men and women in our cohort. In addi-
phrotic syndrome and histological stage III-IV deter-tion, the variables chosen for multivariable analysis, as
mined at the time of diagnostic renal biopsy permit thewell as their definitions, were different.
demarcation of the high-risk group for ESRF from pa-In our cohort the severity of renal functional impair-
tients at lower risk. For the remaining patients, the devel-ment is represented in the final set of predictors by the
opment of high-grade persistent proteinuria in their clini-variable “nephrotic syndrome,” which was defined in
cal course may help identify a further risk group withthis study as proteinuria of more than 3.5 g/day, together
unfavorable prognosis [26].with a decrease of serum albumin to less than 3.0 g/dl
The risk stratification developed in our study can helpand edema. Our findings emphasize the independent
investigators to focus on the high-risk group in futureprognostic impact of severity of proteinuria in patients
clinical trials to delineate the long-term effectiveness ofwith idiopathic membranous nephropathy, and are simi-
immunosuppressive agents in preventing ESRF in idio-lar to recent data described for patients with idiopathic
pathic membranous nephropathy [27, 28].membranous nephropathy [24] and patients with nondia-
betic chronic nephropathies [25]. In our study, however,
the only variable that remained in the multivariate model ACKNOWLEDGMENTS
from all the different cut-points chosen for categorizing This research was supported by grants from the Ulrich-Gessler
proteinuria was “nephrotic syndrome.” Stiftung and the Hochschulsonderprogramm II to B.E.M. The results
were presented in part at the 30th Annual Meeting of the AmericanThe morphologic severity of renal disease was re-
Society of Nephrology, San Antonio, November 2–7, 1997 and at theflected by the variable “histologic stage,” that is, the stage
31st Annual Meeting of the American Society of Nephrology, Philadel-
of glomerular lesion at renal biopsy as classified according phia, October 25–28, 1998 (abstracts; J Am Soc Nephrol 8:143 A, 1997;
J Am Soc Nephrol 9:155A, 1998). We are indebted to Professor R.B.to established criteria [8]. The clinical relevance of this
Sterzel, Universita¨tsklinik Erlangen-Nu¨rnberg, Dr. R. Pilgrim, Kreis-variable as a predictor in our study is emphasized by the
krankenhaus Neumarkt, Professor W. Schulz, Klinikum Bamberg, andfact that the histological classification was made in 89% to Professor D. Seybold, Krankenhaus Bayreuth, for their support and
of patients under the supervision of the same highly permission to access their patients’ data.
experienced senior nephropathologist. Interobserver vari-
Reprint requests to Dr. Brigitte E. Marx, Institut fu¨r Qualita¨t imability could, therefore, be kept at a minimum.
Gesundheitswesen Nordrhein, Tersteegenstr. 31, 40474 Du¨sseldorf, Ger-
The measurement of illness severity at baseline and many.
E-mail: bmarx@www.aekno.deits consideration in prognostic analyses is of paramount
Marx and Marx: Prediction in membranous nephropathy 673
DN, Clark WF, Morrin PA, Lavoie S, Canadian Glomerulone-REFERENCES
phritis Study Group: A controlled trial of cyclosporine in patients
with progressive membranous nephropathy. Canadian Glomerulo-1. Glassock RJ, Cohen AH, Adler SG: Membranous glomerulone-
nephritis Study Group. Kidney Int 47:1130–1135, 1992phritis, in The Kidney, edited by Brenner BM, Philadelphia, WB
16. Kircher T, Nelson J, Burdo H: The autopsy as a measure ofSaunders, 1996, pp 1452–1458
accuracy of the death certificate. N Engl J Med 313:1263–1269,2. Cameron JS: Membranous nephropathy: Still a treatment dilemma.
1985N Engl J Med 327:638–639, 1992
17. Kaplan MH, Feinstein AR: The importance of classifying initial3. Remuzzi G, Bertani T, Negri M: Idiopathic membranous ne-
co-morbidity in evaluating the outcome of diabetes mellitus.phropathy. Lancet 342:1277–1280, 1993
J Chronic Dis 27:387–404, 19744. Marx BE, Marx M: Prognosis of idiopathic membranous nephrop-
18. Concato J, Horwitz RI, Feinstein AR, Elmore JG, Schiff SF:athy: A methodologic meta-analysis. Kidney Int 51:873–879, 1997
Problems of comorbidity in mortality after prostatectomy. JAMA5. Marx BE, Feinstein AR: Methodologic sources of prognostic
267:1077–1082, 1992inconsistencies in post-acute myocardial infarction. Am J Med
19. Kaplan EL, Meier P: Nonparametric estimation from incomplete98:537–550, 1995
observations. J Am Stat Assoc 53:457–481, 19586. Wasson JH, Sox HC, Neff RK, Goldman L: Clinical prediction
20. Cox DR: Regression models and life-tables (with discussion). J Rrules: Applications and methodological standards. N Engl J Med
Stat Soc [B] 34:187–220, 1972313:793–797, 1985
21. Schieppati A, Mosconi L, Perna A, Mecca G, Bertani T, Garat-7. Kernan WN, Feinstein AR, Brass LM: A methodological ap-
tini S, Remuzzi G: Prognosis of untreated patients with idiopathicpraisal of research on prognosis after transient ischemic attacks.
membranous nephropathy. N Engl J Med 329:85–89, 1993Stroke 22:1108–1116, 1991
22. Reichert LJM, Koene RAP, Wetzels JFM: Prognostic factors in8. Ehrenreich T, Porush JG, Churg J, Garfinkel L, Glabman S,
idiopathic membranous nephropathy. Am J Kidney Dis 31:1–11,Goldstein MH, Grishman E, Yunis SL: Treatment of idiopathic
1998membranous nephropathy. N Engl J Med 295:741–746, 1976 23. Tu W-H, Petitti DB, Biava CG, Tulunay O¨, Hopper J Jr: Mem-9. Wakai S, Magil AB: Focal glomerulosclerosis in idiopathic mem- branous nephropathy: Predictors of terminal renal failure. Nephronbranous glomerulonephritis. Kidney Int 41:428–434, 1992 36:118–124, 1984
10. Collaborative Study of the Adult Idiopathic Nephrotic Syn- 24. Pei Y, Cattran DC, Greenwood C: Predicting chronic renal insuf-
drome: A controlled study of short-term prednisone treatment in ficiency in idiopathic membranous glomerulonephritis. Kidney Int
adults with membranous nephropathy. N Engl J Med 301:1301– 42:960–966, 1992
1306, 1979 25. Ruggenenti P, Perna A, Mosconi L, Pisoni R, Remuzzi G,
11. Ponticelli C, Zucchelli P, Passerini P, Cagnoli L, Cesana B, Gruppo Italiano di Studi Epidemiologici in Nefrologia: Urinary
Pozzi C, Pasquali S, Imbasciati E, Grassi C, Redaelli B, Sas- protein excretion rate is the best independent predictor of ESRF
delli M, Locatelli F: A randomized trial of methylprednisolone in non-diabetic proteinuric chronic nephropathies. Kidney Int
and chlorambucil in idiopathic membranous nephropathy. N Engl 53:1209–1216, 1998
J Med 320:8–13, 1989 26. Cattran DC, Pei Y, Greenwood CMT, Ponticelli C, Passerini
12. Jindal K, West M, Bear R, Goldstein M: Long-term benefits of P, Honkanen E: Validation of a predictive model of idiopathic
therapy with cyclophosphamide and prednisone in patients with membranous nephropathy: Its clinical and research implications.
membranous glomerulonephritis and impaired renal function. Am Kidney Int 51:901–907, 1997
J Kidney Dis 19:61–67, 1992 27. Ponticelli C, Zucchelli P, Passerini P, Cesana B, Italian Idio-
13. Bruns FJ, Adler S, Fraley DS, Segel DP: Sustained remission pathic Membranous Nephropathy Treatment Study Group:
of membranous glomerulonephritis after cyclophosphamide and Methylprednisolone plus chlorambucil as compared with methyl-
prednisone. Ann Int Med 114:725–730, 1991 prednisolone alone for the treatment of idiopathic membranous
14. Guasch A, Suranyi M, Newton L, Hall BM, Meyers BD: Short- nephropathy. N Engl J Med 327:599–603, 1992
term responsiveness of membranous glomerulopathy to cyclospo- 28. Imperiale TF, Goldfarb S, Berns JS: Are cytotoxic agents benefi-
rine. Am J Kidney Dis 20:472–481, 1992 cial in idiopathic membranous nephropathy? A meta-analysis of
15. Cattran DC, Greenwood C, Ritchie S, Bernstein K, Churchill the controlled trials. J Am Soc Nephrol 5:1553–1558, 1995
